Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
262.00    2.00 (0.77%)
Bid:
252.00
Ask:
262.00
Spread: 10.00 (3.968%)
Market Cap: £234.64m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

23 Jul 2025 07:00

RNS Number : 1038S
Wilmington PLC
23 July 2025
 

23 July 2025

Wilmington plc

 

Year-end trading update

 

Wilmington plc, (LSE: WIL, 'Wilmington', 'the Group') the provider of data, information, education and training in the global Governance, Risk and Compliance ('GRC') markets, today provides a trading update for the year ended 30 June 2025.

 

Revenue growth from the Group's ongoing* businesses is expected to be 11%, led by both recent acquisitions in the HSE sector delivering double-digit percentage growth.

 

As at the half year, seven out of nine businesses grew year on year. Following the portfolio changes last year of two disposals and two acquisitions, and the continuing disruption in the US healthcare insurance market impacting our US events business over a full year, reported revenue is expected to be £101.5m (2024: £126m), with organic** revenue also having decreased 1% due to the US.

 

Operating profit from ongoing* businesses is expected to be up 11%, adjusted*** profit before tax is expected to be £27.7m (2024: £27.6m), with adjusted PBT margin up to 27% (2024: 22%).

 

Cash conversion continued to be strong at 107% of profits, with Group net cash on 30 June 2025 at £41.9m (30 June 2024: £67.8m) after the completion of the acquisition of Phoenix Health & Safety on 25 October 2024 and spending £3.4m on share buybacks.

 

Wilmington expects to publish its year end results on 22 September 2025.

 

Mark Milner, Chief Executive Officer, commented:

 

"We have seen another year of good ongoing* revenue and profit growth with both measures increasing 11%, reflecting our focus on a slimmed down higher quality portfolio of growing businesses. Margins have also continued to improve and both of our recent acquisitions have seen double digit growth. This performance came against a tough macro backdrop, particularly in the US healthcare market which has seen continued disruption in the course of our H2.

 

"With the acquisition of Phoenix, we have continued to actively manage our portfolio of businesses and are pursuing various opportunities to invest our cash in acquisitions to improve the quality of revenue and profits."

 

*Ongoing - eliminating the effects of the impact of disposals, closures and businesses held for sale.

**Organic - Ongoing, eliminating acquisitions and exchange rate fluctuations

***Adjusted profit before tax (PBT) is calculated as PBT after adding back amortisation and impairment of intangible assets (except computer software) and profits/losses on disposals and business closures. Market consensus adjusted profit before tax is £27.0m.

 

For further information, please contact:

 

Wilmington plc

Mark Milner, Chief Executive Officer

Guy Millward, Chief Financial Officer

 

Meare Consulting

Adrian Duffield

 

 

020 7490 0049

 

 

 

 

07990 858548

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for data, information, education and training in the global Governance, Risk and Compliance (GRC) markets. Wilmington employs around 600 people and sells to around 120 countries. Wilmington is listed on the main market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUUUORVWUBUAR
Date   Source Headline
19th Mar 20184:18 pmRNSBoard Change - Correction
19th Mar 201811:34 amRNSHolding(s) in Company
16th Mar 20181:06 pmRNSBoard Change
15th Mar 20183:36 pmRNSHolding(s) in Company
2nd Mar 20182:13 pmRNSDirector/PDMR Shareholding
1st Mar 20189:00 amRNSVoting Rights and Capital
26th Feb 20188:34 amRNSDirector/PDMR Shareholding
22nd Feb 20183:49 pmRNSHolding(s) in Company
22nd Feb 20187:00 amRNSInterim Results
22nd Feb 20187:00 amRNSAppointment of Martin Morgan as Chairman
14th Feb 20182:50 pmRNSHolding(s) in Company
1st Feb 20189:10 amRNSHolding(s) in Company
1st Feb 20189:00 amRNSVoting Rights and Capital
4th Jan 20187:00 amRNSAcquisition of Interactive Medica
2nd Jan 20189:00 amRNSVoting Rights and Capital
18th Dec 20174:43 pmRNSNotification of Interim Results
1st Dec 20177:00 amRNSVoting Rights and Capital
29th Nov 20177:00 amRNSAppointment of new Chief Financial Officer
23rd Nov 201710:34 amRNSDirector/PDMR Shareholding
2nd Nov 20172:43 pmRNSResult of AGM
2nd Nov 20177:00 amRNSAGM and Q1 Trading Update
1st Nov 20179:12 amRNSVoting Rights and Capital
6th Oct 20175:58 pmRNSHolding(s) in Company
5th Oct 20173:45 pmRNSHolding(s) in Company
5th Oct 20173:44 pmRNSHolding(s) in Company
2nd Oct 20172:49 pmRNSVoting Rights and Capital
29th Sep 20179:27 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSProposed Board Change
21st Sep 20171:47 pmRNSDirector/PDMR Shareholding
20th Sep 201711:50 amRNSShare Awards
18th Sep 20172:01 pmRNSVoting Rights and Capital
14th Sep 20172:48 pmRNSDirector/PDMR Shareholding
14th Sep 20179:33 amRNSDirector/PDMR Shareholding
13th Sep 20174:03 pmRNSDirector/PDMR Shareholding
13th Sep 20177:01 amRNSBoard Change
13th Sep 20177:00 amRNSFinal Results
22nd Aug 20171:52 pmRNSNotification of Final Results
18th Aug 20171:11 pmRNSHolding(s) in Company
1st Aug 201712:21 pmRNSVoting Rights and Capital
3rd Jul 20177:00 amRNSVoting Rights and Capital
28th Jun 20179:44 amRNSDirector/PDMR Shareholding
21st Jun 20173:05 pmRNSHolding(s) in Company
16th Jun 20174:35 pmRNSPrice Monitoring Extension
1st Jun 201712:00 pmRNSVoting Rights and Capital
19th May 201711:56 amRNSHolding(s) in Company
18th May 20177:00 amRNSTrading Statement
4th May 20177:00 amRNSProperty Disposal
3rd May 20171:56 pmRNSHolding(s) in Company
2nd May 20172:21 pmRNSVoting Rights and Capital
3rd Apr 201711:33 amRNSVoting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.